Protocol Review and Monitoring System ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) has a well-established system for review, oversight, and support of cancer research conducted by its investigators. The system includes review by (1) Multidisciplinary Disease and Modality Teams for City of Hope (COH) investigator initiated concepts; (2) the Cancer Protocol Review and Monitoring Committee (CPRMC); (3) the Data Safety Monitoring Committee (DSMC); and (4) the COH designated Institutional Review Boards. The offices that support these committees are centralized within COH?s Research Protections Unit and respectively include the Protocol Scientific Review and Monitoring Office (PSRMO), the Data and Safety Monitoring Office (DSMO); and the Office for Human Research Subject Protections (OHRSP). The COHCCC Protocol Review and Monitoring System (PRMS) is focused on the scientific merit of protocols, prioritization and feasibility of trial completions, as well as oversight of the progress of approved research and termination of research that no longer meets criteria for ongoing continuation. The PRMS is overseen by the CPRMC, which coordinates with investigators and multidisciplinary Disease and/or Modality Teams. The CPRMC is administratively supported by the PSRMO. All proposed cancer research must be reviewed and approved by the CPRMC either through a convened review process or through expedited administrative scientific review for prioritization, as permitted by the CCSG for peer-reviewed research, and reviewed for scientific progress on at least an annual basis. The CPRMC has authority to close trials that do not demonstrate scientific progress, and all appeals are evaluated by the CPRMC. The PRMS continues under the leadership of Karen Reckamp, MS, MD, who has chaired the CPRMC since 2012. Dr. Reckamp is appointed by and reports directly to the Cancer Center Director. The PSRMO is under the direction of Amanda Hammond, JD, Sr. Director of the Research Protections Unit who reports to Ashley Baker Lee, COH?s Senior Vice President for Research Operations. The PRMS was conditionally approved in 2012 and received full approval in 2014.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059216
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Sun, Virginia; Crane, Tracy E; Slack, Samantha D et al. (2018) Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. Contemp Clin Trials 68:61-66
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Aslamy, Arianne; Oh, Eunjin; Ahn, Miwon et al. (2018) Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab 103:1966-1976
Abeywardana, Tharindumala; Oh, Myungeun; Jiang, Lei et al. (2018) CARM1 suppresses de novo serine synthesis by promoting PKM2 activity. J Biol Chem 293:15290-15303
Jandial, Rahul; Neman, Josh; Lim, Punnajit P et al. (2018) Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. Int J Mol Sci 19:
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Caserta, Enrico; Chea, Junie; Minnix, Megan et al. (2018) Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 131:741-745
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590

Showing the most recent 10 out of 1396 publications